Evolutionary Ubiquitin Ligase-Based Protein Degradation Platform

A next-generation protein degradation platform that leverages adaptive E3 ubiquitin ligase proteins, machine learning algorithms, and microRNA-programmed nanoparticles to provide a universal solution for targeting disease-associated proteins

The original patent, 'Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide', has limitations in its scope and specificity. The new inventive concept addresses these limitations by introducing a highly adaptable and targeted protein degradation platform that can evolve to address a wide range of disease-associated proteins

The new platform comprises a novel, adaptive E3 ubiquitin ligase protein that can be engineered to target specific disease-associated proteins. This is achieved through the use of machine learning algorithms that predict the efficacy of the ubiquitin ligase-based protein degradation platform against target proteins, generating optimized bifunctional or chimeric constructs for use in the platform. The platform also utilizes microRNA-programmed nanoparticles to deliver these constructs to specific cells or tissues, enabling targeted protein degradation and minimizing off-target effects

The new claims introduce several novel and non-obvious features, including the use of adaptive E3 ubiquitin ligase proteins, machine learning algorithms for optimizing protein degradation, and microRNA-programmed nanoparticles for targeted delivery. These features provide a significant improvement over the original patent, enabling a universal protein degradation solution

Alternative embodiments of the inventive concept could include the use of different types of nanoparticles or delivery mechanisms, or the integration of additional machine learning algorithms to further optimize protein degradation. Variations could also include the development of novel E3 ubiquitin ligase proteins with improved specificity or activity

The evolutionary ubiquitin ligase-based protein degradation platform has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of cancer, neurodegenerative diseases, and rare genetic disorders. The platform's adaptability and targeting capabilities make it an attractive solution for addressing a wide range of disease-associated proteins